Brief: Everest Medicines Announces That Licensing Partner Venatorx Pharmaceuticals Reports Positive Results From Pivotal Phase 3 Cefepime-Taniborbactam Trial
10/03/2022 11:09
March 10 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES THAT LICENSING PARTNER
VENATORX
PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PIVOTAL PHASE 3
CEFEPIME-TANIBORBACTAM TRIAL
* EVEREST MEDICINES LTD - THERE WAS ONE DEATH IN
CEFEPIME-TANIBORBACTAM ARM OF STUDY, WHICH WAS DEEMED UNRELATED
TO STUDY TREATMENT BY INVESTIGATOR
* EVEREST MEDICINES - CEFEPIME-TANIBORBACTAM MET PRIMARY
EFFICACY
ENDPOINT OF STATISTICAL NI TO MEROPENEM IN MICROBIOLOGICAL
INTENT-TO-TREAT POPULATION
Source text for Eikon: ID:nPn9dGLx5a
Further company coverage: 1952.HK
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region